CRBN and Miyoshi myopathy: Mezigdomide demonstrated antiproliferative and proapoptotic properties across MM cell lines, including those exhibiting resistance to lenalidomide and pomalidomide, as well as primary myeloma cells with diminished or mutated CRBN expressions.